ArticleInvestigational new drugs2019

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.

Deaglan McHugh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.